Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, controlled trial of replication-competent adenovirus-mediated suicide gene therapy [HSV thymidine kinase gene therapy] in combination with IMRT [intensity modulated radiotherapy]versus IMRT alone for the treatment of newly-diagnosed Prostate Cancer With an Intermediate Risk Profile.

X
Trial Profile

A randomized, controlled trial of replication-competent adenovirus-mediated suicide gene therapy [HSV thymidine kinase gene therapy] in combination with IMRT [intensity modulated radiotherapy]versus IMRT alone for the treatment of newly-diagnosed Prostate Cancer With an Intermediate Risk Profile.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ad5 yCD/mutTK(SR39)rep ADP (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms ReCAP
  • Most Recent Events

    • 18 Mar 2016 Time frame for primary end point has been changed from 8 years to 5 years as reported by ClinicalTrials.gov record.
    • 08 May 2013 Interim results for the phase II part of the study presented at the 108th Annual Meeting of the American Urological Association.
    • 06 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top